5-CNAC AS ORAL DELIVERY AGENT FOR PARATHYROID HORMONE FRAGMENTS

(19)

(11)

EP 1 420 827 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	23.12.2009 Bulletin 2009/52

(45)	Mention of the grant of the patent:
	23.09.2009 Bulletin 2009/39

(21)	Application number: 02794796.9

(22)	Date of filing: 16.08.2002

(51)

International Patent Classification (IPC):

A61K 47/18^(2006.01)
A61P 19/08^(2006.01)

A61K 38/29^(2006.01)
A61P 19/10^(2006.01)

(86)	International application number:
	PCT/EP2002/009181

(87)	International publication number:
	WO 2003/015822 (27.02.2003 Gazette 2003/09)

(54)	5-CNAC AS ORAL DELIVERY AGENT FOR PARATHYROID HORMONE FRAGMENTS 5-CNAC ZUR ORALEN VERABREICHUNG VON PARATHORMONFRAGMENTEN 5-CNAC UTILISE EN TANT QU'AGENT D'ADMINISTRATION PAR VOIE ORALE POUR DES FRAGMENTS D'HORMONE PARATHYROIDIENNE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
	Designated Extension States:
	RO SI

(30)

Priority:

17.08.2001 US 313048 P

(43)	Date of publication of application:
	26.05.2004 Bulletin 2004/22

(73)	Proprietors:
	Novartis AG 4056 Basel (CH) Designated Contracting States: BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR Novartis Pharma GmbH 1230 Wien (AT) Designated Contracting States: AT

(72)	Inventors:
	AZRIA, Moise CH-4054 Basel (CH) BATEMAN, Simon, David Randolph, NJ 07869 (US)

(74)	Representative: de Weerd, Petrus G.W. et al
	c/o Novartis AG, Geistiges Eigentum Konzern CH 4002 Basel 4002 Basel (CH)

(56)

References cited: :

WO-A-00/59863
US-A- 5 773 647

WO-A-94/07514

LEONE-BAY A ET AL: "ORAL DELIVERY OF BIOLOGICALLY ACTIVE PARATHYROID HORMONE" PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 18, no. 7, July 2001 (2001-07), pages 964-970, XP001106035 ISSN: 0724-8741
LEONE-BAY A ET AL: "SYNTHESIS AND EVALUATION OF COMPOUNDS THAT FACILITATE THE GASTROINTESTINAL ABSORPTION OF HEPARIN" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 41, no. 7, 26 March 1998 (1998-03-26), pages 1163-1171, XP001018961 ISSN: 0022-2623

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).